Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced a multi-target partnership with Boehringer Ingelheim.
Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by Boehringer Ingelheim, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.
“In vivo technologies can work well for many therapeutic targets. However, with increasing demands on selectivity, developability, affinity, and epitopic diversity, mice are often not up to the task,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “Not only are we able to overcome many of those limitations but our engineering capabilities allow us to optimize any lead to become a best-in-class differentiated molecule.”
Under the terms of the agreement, Adimab will use its proprietary yeast-based discovery and optimization platform to identify fully human antibodies against multiple targets selected by Boehringer Ingelheim. For each target, Adimab will grant Boehringer Ingelheim the right to evaluate antibody panels generated during the collaboration for potential use in therapeutic products. Adimab will receive an undisclosed upfront payment, research fees, and delivery milestones. In addition, for each target, Boehringer Ingelheim will have an option to exclusively license antibodies generated during the collaboration as therapeutic leads, for which Adimab would receive license fees, clinical milestones and royalties on product sales.